Blar i NTNU Open på forfatter "Kjerpeseth, Lars Jøran"
-
Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in nonvalvular atrial fibrillation: A nationwide pharmacoepidemiological study
Kjerpeseth, Lars Jøran; Selmer, Randi Marie; Ariansen, Inger; Karlstad, Øystein; Ellekjær, Hanne; Skovlund, Eva (Journal article; Peer reviewed, 2019)Objective: To compare effectiveness and safety of warfarin and the direct oral anticoagulants (DOAC) dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation in routine care. Methods: From nationwide ... -
Oral anticoagulation for stroke prevention in atrial fibrillation Data from the Norwegian Prescription Database, the Norwegian Patient Registry and the Norwegian Cause of Death Registry
Kjerpeseth, Lars Jøran (Doctoral theses at NTNU;2019:160, Doctoral thesis, 2019)Atrieflimmer er den vanligste hjerterytmeforstyrrelsen i Norge og den vestlige verden. Den rammer hyppigere med alderen, særlig etter fylte 60 år. Atrieflimmer starter gjerne som korte anfall som gradvis kommer oftere og ... -
Prevalence and incidence rates of atrial fibrillation in Norway 2004-2014
Kjerpeseth, Lars Jøran; Igland, Jannicke; Selmer, Randi Marie; Ellekjær, Hanne; Tveit, Arnljot; Berge, Trygve; Kalstø, Silje Madeleine; Christophersen, Ingrid E.; Myrstad, Marius; Skovlund, Eva; Egeland, Grace M.; Tell, Grethe S.; Ariansen, Inger (Peer reviewed; Journal article, 2020)Objective To study time trends in incidence of atrial fibrillation (AF) in the entire Norwegian population from 2004 to 2014, by age and sex, and to estimate the prevalence of AF at the end of the study period. Methods A ... -
Risk factors for stroke and choice of oral anticoagulant in atrial fibrillation
Kjerpeseth, Lars Jøran; Ellekjær, Hanne; Selmer, Randi; Ariansen, Inger Kristine Holtermann; Furu, Kari; Skovlund, Eva (Journal article; Peer reviewed, 2018)Purpose To investigate risk factors for stroke in patients initiating oral anticoagulants for atrial fibrillation in Norway and their association with receiving DOACs versus warfarin. Methods From nationwide registries, ... -
Stroke and bleeding risk in atrial fibrillation with CHA2DS2-VASC risk score of one: the Norwegian AFNOR study
Anjum, Mariam; Ariansen, Inger; Hjellvik, Vidar; Selmer, Randi Marie; Kjerpeseth, Lars Jøran; Skovlund, Eva; Myrstad, Marius; Ellekjær, Hanne; Christophersen, Ingrid E.; Tveit, Arnljot; Berge, Trygve (Peer reviewed; Journal article, 2023)Background and Aims The benefit of oral anticoagulant (OAC) therapy in atrial fibrillation (AF) and intermediate stroke risk is debated. In a nationwide Norwegian cohort with a non-sex CHA2DS2-VASc risk score of one, ... -
Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015
Kjerpeseth, Lars Jøran; Ellekjær, Hanne; Selmer, Randi; Ariansen, Inger Kristine; Furu, Kari; Skovlund, Eva (Journal article; Peer reviewed, 2017)Purpose Since 2011, several direct oral anticoagulants (DOACs; dabigatran, rivaroxaban, apixaban) have been introduced as alternatives to warfarin for stroke prophylaxis in atrial fibrillation. We wanted to investigate ... -
Using multiple random index dates with the reverse waiting time distribution improves precision of estimated prescription durations
Bødkergaard, Katrine; Selmer, Randi Marie; Hallas, Jesper; Kjerpeseth, Lars Jøran; Skovlund, Eva; Støvring, Henrik (Peer reviewed; Journal article, 2021)Purpose To improve the precision of prescription duration estimates when using the reverse waiting time distribution (rWTD). Methods For each patient we uniformly sampled multiple random index dates within a sampling ...